HMO Research Network CERT III

描述（由申请人提供）：HMO研究网络CERT提供了关于治疗方法的使用、安全性和有效性的重要见解，并请求资助，以继续利用不同健康计划合作的人群作为治疗证据的可推广来源，并作为传播和实施治疗最佳实践的工具。我们的副主题将是上市后的安全性，尽管我们也将继续积极促进医生和患者的行为改变、信息技术的使用和卫生政策，以优化治疗方法的使用。HMORN CERT的核心将由HMO研究网络的13个健康计划组成，成员总数为1100万。它们都有公共领域的研究单位，与它们的计划的高层领导和交付系统密切相关。HMORN CERT将使用虚拟数据仓库来促进登记、药房、诊断和程序数据的使用，这在促进复杂的多站点研究的同时提供了最高水平的患者隐私。所有网站也都在实施电子病历，允许更大范围的研究。CERT将专注于需要详细数据和/或参与供应商和计划成员的能力的研究。它还将为正在进行的决定（AHRQ）和FDA合同提供关键的基础设施支持，并与nci资助的HMORN癌症研究网络和nih资助的临床转化科学中心合作。新的核心研究将包括实质性和方法学方面的工作：1)药物洗脱冠状动脉支架安全性和有效性的纵向研究；2)通过使用常规收集的电子健康数据，测试快速前瞻性药物安全性评估的新方法；3)儿童抗精神病药物的使用和安全性，重点关注血糖控制异常；4)老年类风湿关节炎使用新型生物制剂的严重感染风险。这些活动将得到其他活动的补充，包括与其他应急中心的有针对性的合作。新的活动将包括：1)公共卫生保健计划联合会，涉及更大的保健计划，进行需要数千万人口的药物/疫苗安全性研究；2)影响医疗保险和医疗补助人群的研究；3)建立临床和经济审查研究所，通过告知合理的覆盖决策，促进具有成本效益的治疗方法的传播；4)教育和传播项目。

DESCRIPTION (Provided by the Applicant): The HMO Research Network CERT has provided important insights into the use, safety and effectiveness of therapies and requests funding to continue leveraging populations from a collaboration of diverse health plans as generalizable sources of therapeutics evidence and as vehicles for disseminating and implementing therapeutics best practices. Our sub-theme will be post-marketing safety, although we will also continue to be active in promoting physician and patient behavior change, the uses of information technology, and health policy to optimize the use of therapeutics. The HMORN CERT's core will consist of 13 health plans of the HMO Research Network, with total membership of 11 million. All have public domain research units strongly linked to their plans' senior leadership and delivery systems. The HMORN CERT will use a Virtual Data Warehouse to facilitate use of enrollment, pharmacy, diagnosis and procedure data, which provides the highest level of patient privacy while facilitating complex multi-site studies. All sites are also implementing electronic medical records, allowing a greater range of studies. The CERT will focus on studies requiring detailed data and/or the ability to engage providers and plan members. It will also provide critical infrastructure support for ongoing DEcIDE (AHRQ) and FDA contracts, and collaborate with the NCI-funded HMORN Cancer Research Network and NIH-funded Clinical Translational Science Centers. New core studies will include both substantive and methodological work: 1) longitudinal study of the safety and efficacy of drug-eluting coronary artery stents; 2) testing new methods for rapid prospective drug safety assessment by using routinely collected electronic health data; 3) use and safety of antipsychotic medications in children, focusing on abnormalities of glycemic control, and 4) risk of serious infection with use of new biological agents for rheumatoid arthritis in the elderly. These will be complemented by additional activities, including targeted collaborations with other CERTs. New activities will include: 1) A Health Plan Consortium for Public Health, involving larger health plans, to perform drug/vaccine safety studies requiring populations of tens of millions; 2) Studies impacting Medicare & Medicaid populations; 3) An Institute for Clinical and Economic Review to facilitate dissemination of cost effective therapies by informing rational coverage decisions; and 4) Education and dissemination programs.